In brief
A study by the Garvan Institute published in Advanced Science analyzed over 400 ER+ breast cancer biopsies and found higher CDK1 activity linked to more aggressive disease and poorer outcomes. The findings suggest CDK1 could serve as a biomarker to identify tumors less likely to respond to CDK4/6 inhibitor therapy, though larger trials are needed to validate the results.
A team of scientists at Australia's Garvan Institute of Medical Research announced that the activity of the protein CDK1 may predict which estrogen‑receptor positive breast cancers will respond to CDK4/6 inhibitors, a widely used class of targeted drugs.
The study, released in a statement by the institute on Friday, focused on estrogen receptor‑positive (ER+) breast cancer, the most common hormone‑driven subtype. Over 400 biopsy samples from patients were examined to determine how CDK1 activity correlated with tumor aggressiveness and patient outcomes.
Researchers found that higher CDK1 activity rose as cancer became more aggressive, and was linked to worse outcomes in patients whose tumors were treated with hormone therapy and CDK4/6 inhibitors. The finding suggests that CDK1 activity may reveal which tumors are less likely to benefit from these targeted therapies.
According to the study published in the journal Advanced Science, the results indicate that CDK1 could serve as a biomarker for personalized therapy. However, the authors emphasize that the findings need to be tested in larger patient groups who receive CDK4/6 inhibitor treatment.
In the statement, researchers mentioned that the new data could eventually open the door to drugs that directly target CDK1, potentially offering alternative options for patients whose cancers are resistant to current CDK4/6 inhibitors.
While the study was limited to a single research institution, the data provide a clear statistical association between CDK1 activity and tumor aggression in ER+ breast cancers. The magnitude of the association was quantified through analysis of more than 400 biopsy samples, providing a robust dataset for initial biomarker evaluation.
Patient groups who receive CDK4/6 inhibitors in combination with hormone therapy currently experience variable responses, with many patients developing resistance over time. Identifying a biomarker that could predict this resistance could guide oncologists toward alternative or additional treatment strategies earlier in the disease course.
The authors note that larger, prospective studies are necessary to confirm that CDK1 activity predicts therapeutic resistance in broader clinical settings. These studies would need to enroll patients receiving standard-of-care CDK4/6 inhibitor therapy and monitor outcomes over longer periods.
Until such trials are completed, the utility of CDK1 as a predictive marker remains an early-stage hypothesis. Nonetheless, the research offers a promising direction toward more individualized treatment plans for patients with ER+ breast cancer.
